<< Physicists observe experimental evidence for directed percolation | NJIT engineer explains the theory behind spontaneous dispersion of particles on liquid surfaces >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Review of point-of-care diagnostic segment

Published on November 20, 2009 at 4:44 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/b6b2b6/monitoring_health) has announced the addition of Decision Resources, Inc.'s new report "Monitoring Health Through Novel Technologies: Where Are We with Point-of-Care Diagnostics?" to their offering.

The point-of-care (POC) diagnostics segment of the in vitro diagnostics field once largely consisted of glucose monitoring devices. With billions of dollars generated in revenue in the United States alone, POC testing has blossomed into a market that incorporates diverse indications and purposes. How has the push for personalized medicine affected change in diagnostics and pharmaceutical companies to warrant a need to align themselves with POC diagnostic test makers? Monitoring health at both acute and chronic disease stages of a patient's life, POC tests can be adapted as clinical and personal tools to improve medical care. However, implementing POC testing to improve health outcomes can be tricky unless regulatory and reimbursement kinks are ironed out in the commercialization strategy for the product. Several prospects exist for advancing POC testing, particularly as the quality of products continues to improve and as efforts to raise awareness of the tests increase.

Get the Answers You Need to Shape Your Strategy

Total revenues in 2008 for the top ten personalized medicine drugs exceeded $6 million.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading